Physician profile
Peter Barcas
NPI 1407838972
$10,374.70
in general payments reported to CMS, 2019-2025
66 companies · $1,602 in 2025
The $1,602 reported for 2025 was more than what 76% of Vascular Neurology providers received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,091 · 2020: $1,224 · 2021: $1,421 · 2022: $1,404 · 2023: $1,707 · 2024: $1,924 · 2025: $1,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,106 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,105.66 |
| Education | $128.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,227.94 | 2020-2025 | |
| Abbvie INC. | $1,134.29 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Pfizer INC. | $1,038.23 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $811.40 | 2019-2025 | Austedo Xr, Austedo Xr |
| Ucb, INC. | $672.86 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Alexion Pharmaceuticals, INC. | $539.53 | 2019-2025 | Ultomiris |
| Lilly USA, LLC | $517.52 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Biogen, INC. | $359.67 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Argenx US, INC. | $249.30 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Acadia Pharmaceuticals INC | $237.12 | 2019-2024 | Nuplazid |
| Janssen Pharmaceuticals, INC | $179.94 | 2020-2023 | Ponvory |
| Sk Life Science, INC. | $178.38 | 2020-2024 | |
| Sunovion Pharmaceuticals INC. | $176.83 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $169.42 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $142.71 | 2020-2021 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Barcas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.